Brief Review

Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors

Masao Takemoto, James K. Liao

Abstract—The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are potent inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the beneficial effects of statins in the primary and secondary prevention of coronary heart disease. However, the overall clinical benefits observed with statin therapy appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels. Indeed, recent experimental and clinical evidence indicates that some of the cholesterol-independent or “pleiotropic” effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, and decreasing oxidative stress and vascular inflammation. Many of these pleiotropic effects of statins are mediated by their ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules. In particular, the inhibition of small GTP-binding proteins, Rho, Ras, and Rac, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in mediating the direct cellular effects of statins on the vascular wall. (Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.)

Key Words: endothelium □ vascular smooth muscle □ platelets □ atherosclerosis □ inflammation

Atherosclerosis is the underlying disorder in the majority of patients with cardiovascular disease.1 Although the development of atherosclerosis is dependent on many factors and processes, a clear association has been established between elevated serum cholesterol levels and increased atherosclerotic disease.2–5 Recent large clinical trials have demonstrated that statins decrease the incidence of coronary heart disease in patients with hypercholesterolemia and atherosclerosis.6–10 Depending on the dose and the type of the statin used, LDL was decreased anywhere from 19% to 60% in response to therapy. In addition, HDL cholesterol levels were increased, and triglycerides were decreased as a result of statin therapy. These lipid effects of statins are believed to slow the progression of atherosclerosis, because atherosclerosis is mediated, in part, by the uptake of modified LDL, which eventually constitutes the lipid core of atherosclerotic lesions.11

Because serum cholesterol levels are strongly associated with coronary atherosclerotic disease,12 it has been generally assumed that cholesterol reduction by statins is the predominant, if not the only, mechanism underlying their beneficial effects in cardiovascular diseases. However, subgroup analyses of large clinical trials have challenged this notion and have suggested that the beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. For example, subgroup analysis of the West of Scotland Coronary Prevention (WOSCOP) and Cholesterol and Recurrent Events (CARE) studies indicates that despite comparable serum cholesterol levels among the statin-treated and placebo groups, statin-treated individuals have a significantly lower risk of coronary heart disease than do age-matched placebo-controlled individuals.8,9,13,14 Furthermore, meta-analyses of cholesterol-lowering trials suggest that the risk of myocardial infarction in individuals treated with statins is significantly lower than that in individuals treated with other cholesterol-lowering agents or modalities despite comparable reduction in serum cholesterol levels in both groups.15,16 These findings suggest that statins may have beneficial effects beyond cholesterol lowering.

Further evidence in support of the noncholesterol benefits of statin therapy is provided by angiographic trials, which have demonstrated clinical improvements with statins that far exceed changes in the size of atherosclerotic lesions. For example, in the Familial Atherosclerosis Treatment Study (FATS) trial, statin therapy with bile acid resin decreased the incidence of coronary events by 70% despite producing only a 0.7% change in lesion regression.15,17 Indeed, many of the beneficial effects of statins in the FATS trial were attributed to plaque stabilization and remodeling. However, in the recent Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) trial, statins were found to be effective in reducing recurrent ischemic events as early as 16 weeks after acute coronary ischemia.18 Although the serum LDL cholesterol was reduced by 40%, this time frame was

Received July 24, 2001; revision accepted August 29, 2001.
From the Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital and Harvard Medical School, Boston, Mass.
Correspondence to Dr James K. Liao, Brigham & Women’s Hospital, 221 Longwood Ave, LMRC-322, Boston, MA 02115. E-mail jliao@rics.bwh.harvard.edu
© 2001 American Heart Association, Inc.
### Pleiotropic Effects of Statins on Vascular Wall Cells

<table>
<thead>
<tr>
<th>Location</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endothelial cells</td>
<td>↑ eNOS expression and activity(^24,46)</td>
</tr>
<tr>
<td></td>
<td>↑ Tissue-type plasminogen activator expression(^49)</td>
</tr>
<tr>
<td></td>
<td>↓ Plasminogen activator inhibitor-1 expression(^49)</td>
</tr>
<tr>
<td></td>
<td>↓ Endothelin-1 synthesis and expression(^50)</td>
</tr>
<tr>
<td></td>
<td>↓ ROS(^47)</td>
</tr>
<tr>
<td></td>
<td>↑ PEROXISOMAL PROLIFERATOR-ACTIVATED RECEPTOR-(\alpha) expression(^113)</td>
</tr>
<tr>
<td></td>
<td>↓ Proinflammatory cytokines (IL-1(\beta), IL-6, cyclooxygenase-2) expression(^113)</td>
</tr>
<tr>
<td></td>
<td>↓ MHC class II antigen expression(^114)</td>
</tr>
<tr>
<td>SMCs</td>
<td>↓ Migration and proliferation(^20,56)</td>
</tr>
<tr>
<td></td>
<td>↓ ROS(^115)</td>
</tr>
<tr>
<td></td>
<td>↓ Rac1-mediated NADH oxidase activity(^115)</td>
</tr>
<tr>
<td></td>
<td>↓ AT(_1) receptor expression(^115)</td>
</tr>
<tr>
<td></td>
<td>↑ Apoptosis(^116)</td>
</tr>
<tr>
<td>Platelets</td>
<td>↓ Platelet reactivity(^68-70)</td>
</tr>
<tr>
<td></td>
<td>↓ Thromboxane A(_2) biosynthesis(^51,72)</td>
</tr>
<tr>
<td>Monocyte/Macrophages</td>
<td>↓ Macrophage growth(^75,117)</td>
</tr>
<tr>
<td></td>
<td>↓ MMP expression and secretion(^75,86)</td>
</tr>
<tr>
<td></td>
<td>↓ Tissue factor expression and activity(^75)</td>
</tr>
<tr>
<td></td>
<td>↓ Inducible NO synthase expression(^118)</td>
</tr>
<tr>
<td></td>
<td>↓ Proinflammatory cytokines (TNF-(\alpha), IL-1(\beta), IL-6) expression(^118)</td>
</tr>
<tr>
<td></td>
<td>↓ Monocyte chemotactant protein-1 secretion(^119)</td>
</tr>
<tr>
<td></td>
<td>↓ IL-8 secretion(^119)</td>
</tr>
<tr>
<td></td>
<td>↓ MHC class II antigen expression(^114)</td>
</tr>
<tr>
<td>Vascular Inflammation</td>
<td>↓ hs-CRP level(^86,106-109)</td>
</tr>
<tr>
<td></td>
<td>↓ Leukocyte-endothelial cell adhesion(^93,94,120)</td>
</tr>
<tr>
<td></td>
<td>↓ Adhesion molecule expression(^91)</td>
</tr>
<tr>
<td></td>
<td>↓ Nuclear factor-(\kappa)B activation(^121)</td>
</tr>
</tbody>
</table>

IL indicates interleukin; MHC, major histocompatibility complex; AT\(_1\), angiotensin type 1; and TNF, tumor necrosis factor.

probably too short for appreciable changes in vascular remodeling. Therefore, it is believed that some other actions of statins, particularly the improvement of endothelial function, may have contributed to these early benefits (Table).\(^19,20\)

### Statins and Isoprenylated Proteins

By inhibiting l-mevalonic acid synthesis, statins also prevent the synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesylpyrophosphate (PPP) and geranylgeranylpyrophosphate (GGPP)\(^21\); see Figure 1. These intermediates serve as important lipid attachments for several components of the atherogenic process. For example, endothelial cell-derived NO mediates vascular relaxation\(^35\) and inhibits platelet aggregation,\(^36\) vascular smooth muscle proliferation,\(^37\) and endothelium-leukocyte interactions.\(^38,39\) Inactivation of NO by superoxide anion (O\(_2^\cdot\)) limits the bioavailability of NO and leads to nitrate tolerance, vasoconstriction, and hypertension.\(^40,41\)

Acute plasma LDL apheresis improves endothelium-dependent vasodilatation,\(^42\) suggesting that statins could re-

### Cholesterol-Independent Effects of Statins

#### Figure 1. Cholesterol biosynthetic pathway. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase by statins decreases the synthesis of isoprenoids and cholesterol. PP indicates pyrophosphate.

- **Acetyl-CoA**
- **HMG-CoA**
- **HMG-CoA Reductase**
- **Mevalonate**
- **Isopentenyl-PP**
- **Geranyl-PP**
- **Deltoic, Farnesylated Protein (i.e., Ras)**
- **Farnesyl-PP**
- **Geranylgeranylated Protein (i.e., Rho, Rap)**
- **Squalene**
- **CHOLESTEROL**

- **Statins**
- **Mevalonate**
- **Isopentenyl-PP**
- **Geranyl-PP**
- **Geranylgeranylated Protein (i.e., Rho, Rap)**
- **Squalene**
- **CHOLESTEROL**

- **Acetyl-CoA**
- **HMG-CoA**
- **HMG-CoA Reductase**
- **Mevalonate**
- **Isopentenyl-PP**
- **Geranyl-PP**
- **Deltoic, Farnesylated Protein (i.e., Ras)**
- **Farnesyl-PP**
- **Geranylgeranylated Protein (i.e., Rho, Rap)**
- **Squalene**
- **CHOLESTEROL**

By inhibiting l-mevalonic acid synthesis, statins also prevent the synthesis of other important isoprenoid intermediates of the cholesterol biosynthetic pathway, such as farnesylpyrophosphate (PPP) and geranylgeranylpyrophosphate (GGPP)\(^21\); see Figure 1. These intermediates serve as important lipid attachments for several components of the atherogenic process. For example, endothelial cell-derived NO mediates vascular relaxation\(^35\) and inhibits platelet aggregation,\(^36\) vascular smooth muscle proliferation,\(^37\) and endothelium-leukocyte interactions.\(^38,39\) Inactivation of NO by superoxide anion (O\(_2^\cdot\)) limits the bioavailability of NO and leads to nitrate tolerance, vasoconstriction, and hypertension.\(^40,41\)

### Statins and Endothelial Function

The vascular endothelium serves as an important autocrine and paracrine organ that regulates vascular wall contractile state and cellular composition. Hypercholesterolemia impairs endothelial function, and endothelial dysfunction is one of the earliest manifestations of atherosclerosis, occurring even in the absence of angiographic evidence of disease.\(^33,34\) An important characteristic of endothelial dysfunction is the impaired synthesis, release, and activity of endothelium-derived NO. Endothelial NO has been shown to inhibit several components of the atherogenic process. For example, endothelium-derived NO mediates vascular relaxation\(^15\) and inhibits platelet aggregation,\(^36\) vascular smooth muscle proliferation,\(^37\) and endothelium-leukocyte interactions.\(^38,39\) Inactivation of NO by superoxide anion (O\(_2^\cdot\)) limits the bioavailability of NO and leads to nitrate tolerance, vasoconstriction, and hypertension.\(^40,41\)

Acute plasma LDL apheresis improves endothelium-dependent vasodilatation,\(^42\) suggesting that statins could re-
Figure 2. Regulation of eNOS expression by statins. Statins inhibit HMG-CoA reductase and block the synthesis of isoprenoids and cholesterol. The isoprenoid, geranylgeranyll (GG), is an important lipid attachment for Rho, which permits the subsequent membrane translocation and activation of Rho. Inhibition of Rho geranylgeranylation by geranylgeranyltransferase inhibitor (GGT), Rho activity by Clostridium botulinum C3 transferase, or Rho kinase activity by Rho kinase inhibitors leads to increases in eNOS expression.

The proliferation of vascular SMCs is a central event in the pathogenesis of vascular lesions, including postangioplasty restenosis, transplant arteriosclerosis, and venous graft occlusion. Recent studies have shown that statins attenuate vascular proliferative disease, such as transplant-associated arteriosclerosis. In contrast to atherosclerosis, transplant-associated arteriosclerosis is more of an immunologic than a lipid disorder, although hypercholesterolemia exacerbates the immunologic process.55 Inhibition of isoprenoid but not cholesterol synthesis by statins decreased platelet-derived growth factor (PDGF)-induced DNA synthesis in vascular SMCs. Treatment with statins decreased PDGF-induced retinoblastoma gene product (Rb) hyperphosphorylation and cyclin-dependent kinase (cdk)-2, cdk-4, and cdk-6 activities. This was correlated with increases in the level of the cdk inhibitor p27Kip1, without concomitant changes in p16INK4a, p21Waf1, or p53 levels. These findings indicate that statins inhibit vascular SMC proliferation by arresting the cell cycle between the G1 phase to S phase transition. It remains to be determined whether the upregulation of p27Kip1 is responsible for the cell cycle arrest and whether there are differences between the various statins in terms of p27Kip1 upregulation.

Because the small GTP-binding proteins, Ras and Rho, require posttranslational modification for membrane localization and activity and are implicated in cell cycle regulation, they are likely targets for the direct antiproliferative vascular effects of statins. Ras can promote cell cycle progression via activation of the mitogen-activated protein kinase pathway57 whereas Rho causes cellular proliferation possibly through destabilizing p27Kip1 protein.58 Interestingly, inhibition of vascular SMC proliferation by statins was reversed by GGPP, but not FPP or LDL cholesterol.30 Indeed, direct inhibition of Rho by Clostridium botulinum C3 transferase, which ADP-ribosylates and inactivates Rho, or by a dominant-negative Rho mutant increased p27Kip1 and inhibited Rb hyperphosphorylation and SMC proliferation after PDGF stimulation.30 Taken together, these findings indicate that Rho mediates PDGF-induced SMC proliferation and that inhibition of Rho by statins is the predominant mechanism by which statins inhibit vascular SMC proliferation.

Statins and Platelet Function

Platelets play a critical role in the development of acute coronary syndromes. Acute thrombus formation at the site of plaque rupture and vascular injury accounts for most episodes of acute coronary syndromes. Hypercholesterolemia is associated with increases in platelet reactivity. These abnormalities are linked to increases in the cholesterol/phospholipid ratio in platelets. Other potential mechanisms include increases in thromboxane A2 biosynthesis, platelet α,-adrenergic receptor density, and platelet cytosolic calcium.

Statins have been shown to inhibit platelet function. Potential mechanisms include a reduction in the production of thromboxane A2 and modifications in the cholesterol content of platelet membranes. The cholesterol content of platelet and erythrocyte membranes is reduced in patients undergoing statin therapy. This may lead to a decrease in the thrombogenic potential of these cells. Indeed, animal studies suggest...
that statin therapy inhibits platelet deposition on damaged vessels and reduces platelet thrombus formation.\textsuperscript{61,73,74} Furthermore, in vitro experiments have demonstrated that statins inhibit tissue factor expression by macrophages, thereby potentially reducing the thrombotic potential of the vascular wall.\textsuperscript{75}

Statins and Plaque Stability

Plaque rupture is a major cause of acute coronary syndromes.\textsuperscript{34,76–79} The atherosclerotic lesion contains highly thrombogenic materials in the lipid core that are separated from the bloodstream by a fibrous cap.\textsuperscript{80} Fissuring, erosion, and ulceration of the fibrous cap eventually leads to plaque rupture and ensuing thrombosis.\textsuperscript{78} Collagen is the main component of fibrous caps and is responsible for their tensile strength. Because macrophages are capable of degrading the collagen-containing fibrous cap, they play an important role in the development and subsequent stability of atherosclerotic plaques.\textsuperscript{81,82} Indeed, degradation of the plaque matrix appears to be most active in macrophage-rich regions.\textsuperscript{76,77} Secretion of proteolytic enzymes, such as matrix metalloproteinases (MMPs), by activated macrophages may weaken the fibrous cap, particularly at the “vulnerable” shoulder region, where the fibrous cap joins the arterial wall.\textsuperscript{83,84} Weakened fibrous caps lead to plaque instability, rupture, and ensuing thrombosis, which ultimately present as acute coronary syndromes.\textsuperscript{79,85}

Lipid lowering by statins may contribute to plaque stability by reducing plaque size or by modifying the physiochemical properties of the lipid core.\textsuperscript{86,87} However, as mentioned previously, changes in plaque size by lipid lowering tend to occur over extended time and are quite minimal, as assessed by angiography. Rather, the clinical benefits from lipid lowering are probably due to decreases in macrophage accumulation in atherosclerotic lesions and inhibition of MMP production by activated macrophages.\textsuperscript{75} Indeed, statins inhibit the expression of MMPs and tissue factor by cholesterol-dependent and -independent mechanisms,\textsuperscript{75,86,88} with the cholesterol-independent or direct macrophage effects occurring at a much earlier time frame. Therefore, the plaque-stabilizing properties of statins are mediated through a combined reduction in lipids, macrophages, and MMPs.\textsuperscript{89} These effects of statins may reduce the incidence of acute coronary syndromes by lessening the propensity for plaque to rupture.

Statins and Vascular Inflammation

Atherosclerosis is a complex inflammatory process that is characterized by the presence of monocytes or macrophages and T lymphocytes in the atheroma.\textsuperscript{11,90} Inflammatory cytokines secreted by these macrophages and T lymphocytes can modify endothelial function, SMC proliferation, collagen degradation, and thrombosis.\textsuperscript{79} An early step in atherogenesis involves monocyte adhesion to the endothelium and penetration into the subendothelial space.\textsuperscript{83} Recent studies suggest that statins possess anti-inflammatory properties by their ability to reduce the number of inflammatory cells in atherosclerotic plaques.\textsuperscript{71} The mechanisms have yet to be fully elucidated but may involve inhibition of adhesion molecules such as intercellular adhesion molecule-1, which are involved in the recruitment of inflammatory cells.\textsuperscript{91} Indeed, a recent study has shown that statins can suppress the inflammatory response independent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition by binding directly to a novel regulatory site of the β\textsubscript{2} integrin, leukocyte function antigen-1, which serves as a major counterreceptor for intercellular adhesion molecule-1 on leukocytes.\textsuperscript{92} Furthermore, statins protect the ischemic myocardium by attenuating P-selectin expression and leukocyte adhesion in normocholesterolemic and diabetic animals.\textsuperscript{93–97} These cholesterol-independent effects of statins were absent in eNOS-deficient or NO\textsuperscript{2}nitro-l-arginine methyl ester–treated mice, suggesting that eNOS mediated the vascular protective effects of statins.

A clinical marker of inflammation is high-sensitivity C-reactive protein (hs-CRP).\textsuperscript{98} hs-CRP is an acute-phase reactant that is produced by the liver in response to proinflammatory cytokines, such as interleukin-6, and reflects low-grade systemic inflammation.\textsuperscript{99} Elevated levels of hs-CRP have been shown to be predictive of increased risk of coronary artery disease in apparently healthy men and women.\textsuperscript{36,100–103} hs-CRP is elevated in patients with coronary artery disease, coronary ischemia, and myocardial infarction compared with normal subjects.\textsuperscript{43,104,105} Statin therapy lowers hs-CRP levels in hypercholesterolemic patients.\textsuperscript{98,106,107} In the CARE trial, statins significantly decreased plasma hs-CRP levels over a 5-year period in patients who did not experience recurrent coronary events.\textsuperscript{108,109} Similarly, an analysis of baseline and 1-year follow-up from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) demonstrated that hs-CRP levels were reduced in statin-treated patients who were free of acute major coronary events.\textsuperscript{98} Therefore, these studies indicate that statins are effective in decreasing systemic and vascular inflammation. However, any potential clinical benefits conferred by the lowering of hs-CRP are difficult to separate from the benefits of the lipid-lowering effects of statins without performing further clinical studies.

Statins and Ischemic Stroke

An intriguing result of large clinical trials with statins is the reduction in ischemic stroke.\textsuperscript{110} Although myocardial infarction is closely associated with serum cholesterol levels, neither the Framingham Heart Study nor the Multiple Risk Factor Intervention Trial (MRFIT) demonstrated significant correlation between ischemic stroke and serum cholesterol levels.\textsuperscript{5,111} Thus, the findings of these large statin trials raise the interesting question of how a class of cholesterol-lowering agents can reduce ischemic stroke when ischemic stroke is not related to cholesterol levels. It appears likely that there are pleiotropic effects of statins that are beneficial in ischemic stroke. Some of these beneficial effects of statins in ischemic stroke may be due, in part, to their ability to upregulate eNOS expression and activity.\textsuperscript{24,46} For example, mice that were prophylactically treated with statins for up to 2 weeks had 25% to 30% higher cerebral blood flow and 50% smaller cerebral infarct sizes after cerebrovascular occlusion.\textsuperscript{26,112} No increase in cerebral blood flow or neuroprotection was observed in eNOS-deficient mice treated with statins, indicating that the upregulation of eNOS accounts for most, if not all, of the neuroprotective effects of these agents. Interestingly, treatment with statins did not affect blood pressure or heart rate before, during, or after cerebrovascular ischemia and did not alter serum cholesterol levels in mice,
consistent with the cholesterol-independent neuroprotective effects of statins. In addition to increases in cerebral blood flow, other beneficial effects of statins that have an impact on the severity of ischemic stroke are likely to occur. For example, statins attenuate P-selectin expression and leukocyte adhesion via increases in NO production in a model of cardiac ischemia and reperfusion.93,96 Others have reported that statins upregulate tissue-type plasminogen activator and downregulate plasminogen activator inhibitor-1 expression through a similar mechanism involving the inhibition of Rho geranylgeranylation.49 Thus, the absence of neuroprotection in eNOS-deficient mice emphasizes the importance of endothelium-derived NO not only in augmenting cerebral blood flow but also, potentially, in limiting the impact of platelet and white blood cell accumulation on tissue viability after ischemia. It is possible that statins may have contributed to the decrease in the incidence of ischemic strokes in clinical trials, in part, by reducing cerebral infarcts size to levels that are clinically unpunappreciated.

Summary

Statins exert many pleiotropic effects on the vascular wall. These include beneficial effects on endothelial function and blood flow, decreasing LDL oxidation, enhancing the stability of atherosclerotic plaques, inhibiting vascular SMC proliferation and platelet aggregation, and reducing vascular inflammation (Figure 3). Recent evidence suggests that most of these effects are mediated by the inhibitory effect of statins on isoprenoid synthesis. In particular, inhibition of Rho GTPases in vascular wall cells by statins leads to increased activity of atherosclerotic plaques, inhibiting vascular SMC proliferation and hypertrophy, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress, preventing thrombotic responses, and attenuating vascular inflammation. ET-1 indicates endothelin-1; AT1 receptor, angiotensin type 1 receptor; TF, tissue factor; t-PA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; and TXA2, thromboxane A2.

Figure 3. Effects of statins on vascular wall cells. Summary of the cholesterol-independent effects of statins, which include improving endothelial function, inhibiting SMC proliferation and hypertrophy, enhancing the stability of atherosclerotic plaques, decreasing oxidative stress, preventing thrombotic responses, and attenuating vascular inflammation. ET-1 indicates endothelin-1; AT1 receptor, angiotensin type 1 receptor; TF, tissue factor; t-PA, tissue-type plasminogen activator; PAI-1, plasminogen activator inhibitor-1; and TXA2, thromboxane A2.

Acknowledgments

The work described in this article was supported in part by the National Institutes of Health (HL-52233, HL-48743, HL-62602, and NS-10828) and the American Heart Association Bugher Foundation Award. Dr Liao is an Established Investigator of the American Heart Association. Dr Takemoto is a recipient of a Banyu-Merck Fellowship.

References


Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters.

Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change.

Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A.


Radomski MW, Rees DD, Dutra A, Moncada S, S-Nitroso-thiol.


Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Masao Takemoto and James K. Liao

doi: 10.1161/hq1101.098486
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/21/11/1712

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/